TR201901991T4 - Prostat spesifik kök hücre antijenine karşı antikor ve bunun kullanımı. - Google Patents

Prostat spesifik kök hücre antijenine karşı antikor ve bunun kullanımı. Download PDF

Info

Publication number
TR201901991T4
TR201901991T4 TR2019/01991T TR201901991T TR201901991T4 TR 201901991 T4 TR201901991 T4 TR 201901991T4 TR 2019/01991 T TR2019/01991 T TR 2019/01991T TR 201901991 T TR201901991 T TR 201901991T TR 201901991 T4 TR201901991 T4 TR 201901991T4
Authority
TR
Turkey
Prior art keywords
antibody
seq
psca
antibodies
amino acid
Prior art date
Application number
TR2019/01991T
Other languages
English (en)
Turkish (tr)
Inventor
Bachmann Michael
Original Assignee
Gemoab Monoclonals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemoab Monoclonals Gmbh filed Critical Gemoab Monoclonals Gmbh
Publication of TR201901991T4 publication Critical patent/TR201901991T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
TR2019/01991T 2011-06-30 2012-06-29 Prostat spesifik kök hücre antijenine karşı antikor ve bunun kullanımı. TR201901991T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102011118022.6A DE102011118022B4 (de) 2011-06-30 2011-06-30 Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung

Publications (1)

Publication Number Publication Date
TR201901991T4 true TR201901991T4 (tr) 2019-03-21

Family

ID=46384405

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/01991T TR201901991T4 (tr) 2011-06-30 2012-06-29 Prostat spesifik kök hücre antijenine karşı antikor ve bunun kullanımı.

Country Status (18)

Country Link
US (1) US9200078B2 (cg-RX-API-DMAC7.html)
EP (2) EP2726507B1 (cg-RX-API-DMAC7.html)
JP (4) JP2014528696A (cg-RX-API-DMAC7.html)
AU (1) AU2012277784B2 (cg-RX-API-DMAC7.html)
CY (1) CY1121249T1 (cg-RX-API-DMAC7.html)
DE (1) DE102011118022B4 (cg-RX-API-DMAC7.html)
DK (1) DK2726507T3 (cg-RX-API-DMAC7.html)
ES (2) ES2711978T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20190289T1 (cg-RX-API-DMAC7.html)
HU (1) HUE042008T2 (cg-RX-API-DMAC7.html)
LT (1) LT2726507T (cg-RX-API-DMAC7.html)
PL (1) PL2726507T3 (cg-RX-API-DMAC7.html)
PT (1) PT2726507T (cg-RX-API-DMAC7.html)
RS (1) RS58448B1 (cg-RX-API-DMAC7.html)
SI (1) SI2726507T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900085T1 (cg-RX-API-DMAC7.html)
TR (1) TR201901991T4 (cg-RX-API-DMAC7.html)
WO (1) WO2013001065A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011118022B4 (de) * 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
CA3221995C (en) 2017-02-08 2024-05-28 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201907646YA (en) 2017-02-20 2019-09-27 Dragonfly Therapeutics Inc Proteins binding her2, nkg2d and cd16
WO2019066093A1 (ko) * 2017-09-26 2019-04-04 주식회사 와이바이오로직스 Scf 특이적 항체
PT3749346T (pt) 2018-02-08 2024-09-05 Dragonfly Therapeutics Inc Combinações de domínios variáveis de anticorpos dirigidas ao receptor nkg2d
KR20200118824A (ko) 2018-02-08 2020-10-16 드래곤플라이 쎄라퓨틱스, 인크. 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법
CA3091424A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
CA3108646A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
AU2019318083A1 (en) 2018-08-08 2021-02-25 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
CN116406381A (zh) * 2020-05-19 2023-07-07 希望之城 工程化抗前列腺干细胞抗原融合蛋白及其用途
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
WO2024233662A2 (en) * 2023-05-09 2024-11-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to psca polypeptides
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541212B2 (en) * 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
NZ337413A (en) * 1997-03-10 2003-02-28 Univ California Antibodies that bind to Prostate Stem Cell Antigen (PSCA) to treat prostate cancer.
ES2309012T3 (es) * 1999-10-29 2008-12-16 Genentech, Inc. Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca.
KR20120125634A (ko) * 2003-10-16 2012-11-16 마이크로메트 에이지 다중특이적 탈면역화된 ｃｄ3-바인더
EP1753871B1 (en) * 2004-05-28 2015-07-15 Agensys, Inc. Antibodies and related molecules that bind to psca proteins
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
RU2547600C2 (ru) * 2008-10-01 2015-04-10 Эмджен Рисерч (Мьюник) Гмбх Pscaxcd3, cd19xcd3, c-metxcd3, эндосиалинxcd3, epcamxcd3, igf-1rxcd3 или fap-альфаxcd3 биспецифическое одноцепочечное антитело с межвидовой специфичностью
US20110142811A1 (en) * 2009-12-16 2011-06-16 Deutsches Krebsforschungszentrum Measles virus for the elimination of unwanted cell populations
DE102011118022B4 (de) * 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung

Also Published As

Publication number Publication date
EP2726507B1 (de) 2018-11-21
EP3505536B1 (de) 2024-08-07
JP2019193652A (ja) 2019-11-07
AU2012277784A1 (en) 2014-02-06
US20140134155A1 (en) 2014-05-15
DK2726507T3 (en) 2019-03-11
JP6549622B2 (ja) 2019-07-24
JP6886491B2 (ja) 2021-06-16
PT2726507T (pt) 2019-02-26
DE102011118022A1 (de) 2013-01-03
JP2021121201A (ja) 2021-08-26
ES2989975T3 (es) 2024-11-28
JP2014528696A (ja) 2014-10-30
ES2711978T3 (es) 2019-05-08
US9200078B2 (en) 2015-12-01
JP2017104113A (ja) 2017-06-15
DE102011118022B4 (de) 2018-01-18
HUE042008T2 (hu) 2019-06-28
EP3505536C0 (de) 2024-08-07
HRP20190289T1 (hr) 2019-05-03
RS58448B1 (sr) 2019-04-30
JP7341185B2 (ja) 2023-09-08
SMT201900085T1 (it) 2019-05-10
EP3505536A1 (de) 2019-07-03
CY1121249T1 (el) 2020-05-29
LT2726507T (lt) 2019-04-10
EP2726507A1 (de) 2014-05-07
WO2013001065A1 (de) 2013-01-03
AU2012277784B2 (en) 2015-08-20
PL2726507T3 (pl) 2019-06-28
SI2726507T1 (sl) 2019-05-31

Similar Documents

Publication Publication Date Title
JP7341185B2 (ja) 前立腺特異幹細胞抗原に対する抗体およびその使用
JP7577435B2 (ja) Ｃｌｄｎ１８．２及びｃｄ３に対する抗体コンストラクト
AU2010299895B2 (en) Anti-CD33 antibodies and use thereof for immunotargeting in treating CD33-associated illnesses
EP2850106B1 (en) Bispecific scfv immunofusion (bif) binding to cd123 and cd3
JP7056858B2 (ja) 新規な組換え型二機能性融合タンパク質、その調製方法および用途
AU2011287552B2 (en) Antibodies against 6-sulfo-LacNAc-positive human dendritic cells, and their use
CN119137147A (zh) 具有增加的选择性的多链多靶向性双特异性抗原结合分子
CN111479827B (zh) 结合hERG1和hERG1/整联蛋白β1的单特异性和双特异性抗体
KR20220082776A (ko) 항-tigit 항체 및 이의 용도
JP2025536561A (ja) メソテリンに対する親和度が上昇されたキメリック抗原受容体、及びその用途
HK40081697A (en) Bispecific scfv immunofusion (bif) binding to cd123 and cd3
HK1197419A (en) Antibodies against prostate-specific stem cell antigen and use thereof
KR20220143904A (ko) 사람 4-1bb 항진제 항체 및 이의 사용 방법
HK1197419B (en) Antibodies against prostate-specific stem cell antigen and use thereof
Paton Construction and characterisation of anti-tumour antibody-based proteins for use in diagnostics and therapeutics